Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
- PMID: 31820981
- DOI: 10.1021/acs.jmedchem.9b01180
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
Abstract
KRASG12C has emerged as a promising target in the treatment of solid tumors. Covalent inhibitors targeting the mutant cysteine-12 residue have been shown to disrupt signaling by this long-"undruggable" target; however clinically viable inhibitors have yet to be identified. Here, we report efforts to exploit a cryptic pocket (H95/Y96/Q99) we identified in KRASG12C to identify inhibitors suitable for clinical development. Structure-based design efforts leading to the identification of a novel quinazolinone scaffold are described, along with optimization efforts that overcame a configurational stability issue arising from restricted rotation about an axially chiral biaryl bond. Biopharmaceutical optimization of the resulting leads culminated in the identification of AMG 510, a highly potent, selective, and well-tolerated KRASG12C inhibitor currently in phase I clinical trials (NCT03600883).
Similar articles
-
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.Nature. 2019 Nov;575(7781):217-223. doi: 10.1038/s41586-019-1694-1. Epub 2019 Oct 30. Nature. 2019. PMID: 31666701 Clinical Trial.
-
Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96.ACS Chem Biol. 2024 Oct 18;19(10):2152-2164. doi: 10.1021/acschembio.4c00315. Epub 2024 Sep 16. ACS Chem Biol. 2024. PMID: 39283696
-
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.Cancer Discov. 2021 Aug;11(8):1913-1922. doi: 10.1158/2159-8290.CD-21-0365. Epub 2021 Apr 6. Cancer Discov. 2021. PMID: 33824136 Free PMC article.
-
Targeting mutant KRAS.Curr Opin Chem Biol. 2021 Jun;62:101-108. doi: 10.1016/j.cbpa.2021.02.010. Epub 2021 Apr 7. Curr Opin Chem Biol. 2021. PMID: 33838397 Review.
-
Inhibition of RAS: proven and potential vulnerabilities.Biochem Soc Trans. 2020 Oct 30;48(5):1831-1841. doi: 10.1042/BST20190023. Biochem Soc Trans. 2020. PMID: 32869838 Free PMC article. Review.
Cited by
-
Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.Nat Commun. 2024 Sep 25;15(1):8146. doi: 10.1038/s41467-024-52324-3. Nat Commun. 2024. PMID: 39322643 Free PMC article.
-
Targeted Covalent Inhibitors in Drug Discovery, Chemical Biology and Beyond.Pharmaceuticals (Basel). 2024 Feb 5;17(2):206. doi: 10.3390/ph17020206. Pharmaceuticals (Basel). 2024. PMID: 38399421 Free PMC article.
-
Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.J Clin Oncol. 2020 Dec 10;38(35):4208-4218. doi: 10.1200/JCO.20.00744. Epub 2020 Oct 26. J Clin Oncol. 2020. PMID: 33104438 Free PMC article. No abstract available.
-
Puckering the Planar Landscape of Fragments: Design and Synthesis of a 3D Cyclobutane Fragment Library.ChemMedChem. 2022 May 4;17(9):e202200113. doi: 10.1002/cmdc.202200113. Epub 2022 Mar 30. ChemMedChem. 2022. PMID: 35277937 Free PMC article.
-
Targeting protein conformations with small molecules to control protein complexes.Trends Biochem Sci. 2022 Dec;47(12):1023-1037. doi: 10.1016/j.tibs.2022.07.002. Epub 2022 Aug 16. Trends Biochem Sci. 2022. PMID: 35985943 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases
Miscellaneous